RNF43 p.G659fs 通过 PI3K/AKT/mTOR 信号通路和 HLA-E 上调导致 MSI-high 结直肠癌中 NK 细胞功能障碍
RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Identification of a ferroptosis-related lncRNA signature with prognosis for Wilms tumor.
Identification of a ferroptosis-related lncRNA signature with prognosis for Wilms tumor.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
基于我们的分析,我们构建了一个与铁死亡相关的 lncRNA 特征,该特征既能评估 WT 患者的预后,也可能为未来的 WT 治疗提供依据。
肾母细胞瘤(WT)是儿童中常见的泌尿系统肿瘤。铁死亡则是一种与肿瘤发展相关的新型细胞死亡形式。本研究旨在探究铁死亡相关生物标志物预测WT患者预后的能力。
为明确铁死亡相关基因表达与WT预后的关系,研究首先从TARGET数据库收集124例WT和6份健康组织样本的RNA测序数据及临床信息。随后通过Cox回归分析筛选铁死亡相关长链非编码RNA(lncRNA),构建特征模型及预后列线图。最后探讨铁死亡相关lncRNA与肿瘤免疫的潜在关系,并筛选可能的免疫检查点。
研究构建了包含12个铁死亡相关lncRNA的WT预后预测特征。ROC曲线预测1年、3年和5年总生存率的曲线下面积分别为.775、.867和.891。此外,研究利用临床特征和风险评分生成了列线图,其C指数为.836,提示预测价值较高。低危和高危WT患者之间存在显著肿瘤免疫差异,尤其体现在B细胞、NK细胞、Th1细胞、Treg细胞、促炎反应以及I型和II型IFN应答方面。此外,研究显示SIRPA、ICOSLG、LAG3、PVRIG、NECTIN1和SIRPB2等免疫检查点可能成为WT的潜在治疗靶点。
根据分析,研究构建了一个铁死亡相关lncRNA特征,可用于评估WT患者预后,并可能为未来WT治疗提供依据。
Wilms tumor (WT) is a widespread urologic tumor in children. Ferroptosis, on the other hand, is a novel form of cell death associated with tumor development. In this study, we aim to explore the predictability of ferroptosis-related biomarkers in estimating prognosis in WT patients.
To determine a link between ferroptosis-related gene expression and WT prognosis, we first collected RNA sequencing data and clinical information, involving 124 WT and 6 healthy tissue samples, from the TARGET database. Next, we screened the collected information for ferroptosis-related long non-coding RNA using Cox regression analysis, and constructed a signature model, as well as a nomogram, related to prognosis. Finally, we explored a potential link between ferroptosis-related lncRNA and tumor immunity and screened for possible immune checkpoints.
We constructed a WT prognosis prediction signature containing 12 ferroptosis-related lncRNAs. The area under the curves values, from the ROC curves, predicting overall survival rates at the 1, 3-, and 5-year timepoints were 0.775, 0.867, and 0.891 respectively. Moreover, we generated a nomogram, using clinical features and risk scores, carrying a C-index value of 0.836, which suggested a high predictive value. We also demonstrated significant differences in tumor immunity between low- and high-risk WT patients, particularly in the presence of B cells, NK cells, Th1 cells, Treg cells, inflammation promoting, and type I and II IFN responses. In addition, we showed that immune checkpoints like SIRPA , ICOSLG , LAG3 , PVRIG , NECTIN1 , and SIRPB2 can serve as potential therapeutic targets for WT.
Based on our analyses, we generated a ferroptosis-related lncRNA signature that can both estimate prognosis of WT patients and may provide basis for future WT therapy.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。